Monday, June 14, 2021

Tag: ReNetX Bio

ReNetX Bio Receives Fast Track Designation From U.S. FDA

Potential First-in-Class Therapy for Chronic Spinal Cord Injury NEW HAVEN, Conn., Jan. 08, 2020 (GLOBE NEWSWIRE) -- ReNetX Bio announced today that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track Designation for...

Drug aims to help treat spinal cord injuries

Researchers at ReNetX Bio are hoping a new name, the potential for a new influx of cash on the horizon and a new chief executive officer are the winning combination needed to bring its...